Network biology meets
drug discovery
We engineer medicine based not on a single target, but the biological network as a whole.
+100,000
Proprietary
Chemotranscriptomes
Chemotranscriptomes
+2.3B
mRNAs Measured
4
Drug Programs
Our Technology
Chemotranscriptomes
Arpeggio is developing the world's fastest platform for transcriptomic sequencing to learn how chemistry maps to network biology.
Our Pipeline
Chronic disease
99.5% of adults over fifty will have a chronic disease by 2040. We're working on developing a pipeline of potential drugs to tackle drug resistance in cancer, chronic kidney disease, and neurodegeneration.
Featured news
Arpeggio Raises $17M in Series A
We have partnered with Builders VC, and many returning investors, to develop our pipeline of transcriptomic medicine.
Arpeggio Raises $17M in Series A
We have partnered with Builders VC, and many returning investors, to develop our pipeline of transcriptomic medicine.
CBSA Rising Star Finalist
Arpeggio is selected as a finalist for the Rising Star of the Year Award by the Colorado BioScience Association.
CBSA Rising Star Finalist
Arpeggio is selected as a finalist for the Rising Star of the Year Award by the Colorado BioScience Association.
Targeted Oncology
In collaboration with Forma Therapeutics, Arpeggio uses their transcriptional platform to uncover novel mechanisms of CBP inhibitors.
Targeted Oncology
In collaboration with Forma Therapeutics, Arpeggio uses their transcriptional platform to uncover novel mechanisms of CBP inhibitors.
